Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 19/20 | 1.00 |
| ▸ | RPS6KB1 | P23443 | 9/20 | 0.78 |
| ▸ | AURKA | O14965 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15762453 | 1.00 | AKT1 (1.00) | AKT1RPS6KB1AURKA | |
| SCHEMBL15762711 | 0.92 | AKT1 (0.85) | AKT1RPS6KB1AURKA | |
| SCHEMBL22115907 | 0.92 | AKT1 (0.85) | AKT1RPS6KB1AURKA | |
| SCHEMBL20178077 | 0.89 | AKT1 (1.00) | AKT1RPS6KB1 | |
| SCHEMBL15762437 | 0.89 | AKT1 (1.00) | AKT1RPS6KB1 | |
| SCHEMBL15762430 | 0.88 | AKT1 (1.00) | AKT1RPS6KB1 | |
| SCHEMBL20178064 | 0.88 | AKT1 (1.00) | AKT1RPS6KB1 | |
| SCHEMBL15762433 | 0.87 | AKT1 (1.00) | AKT1RPS6KB1 | |
| SCHEMBL20178087 | 0.87 | AKT1 (1.00) | AKT1RPS6KB1 | |
| SCHEMBL15762456 | 0.87 | AKT1 (1.00) | AKT1RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105793254-B | Azaquinazoline carboxamide derivatives | 默克专利有限公司 | 2020-10-23 | — | — | CN | claimed |
| EP-2925747-B1 | AZAQUINAZOLINE CARBOXAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-06-24 | — | — | EP | disclosed |
| US-10233160-B2 | Substituted pyrido[3,4-d]pyrimidines and pyrido[4,3-d]pyrimidines as p70S6K inhibitors | MERCK PATENT GMBH (DE) | 2019-03-19 | — | — | US | disclosed |
| US-20180237402-A1 | AZAQUINAZOLINE CARBOXAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-08-23 | — | — | US | disclosed |
| US-9981925-B2 | Substituted benzo[d][1,2,3]triazines as p70S6K inhibitors | MERCK PATENT GMBH (DE) | 2018-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180237402-A1 | AZAQUINAZOLINE CARBOXAMIDE DERIVATIVES | RPS6KA3, RPS6KA4, CDK4 | AKT1 415/4885RPS6KB1 16/4885AURKA 458/4885 |
| US-10233160-B2 | Substituted pyrido[3,4-d]pyrimidines and pyrido[4,3-d]pyrimidines as p70S6K inhibitors | CDK4, CDK2, RPS6KA4 | AKT1 372/4885RPS6KB1 17/4885AURKA 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.